The Year in Review session during ACR Convergence 2020 will address advances in clinical and basic science related to rheumatology, including drug safety, precision medicine, the COVID-19 pandemic and more.
Leveraging the ACR’s RISE Registry for Research
I have always been dissatisfied with the apparent dichotomy between researchers and clinicians; this is a false divide. Yes, research includes laboratory-based investigation, clinical trials, and retrospective and prospective studies of disease entities, among other pursuits. However, clinicians also contribute to research by sharing clinical data and through observations of their patients. Clinicians’ daily contributions…
Precision Medicine Today: Predicting Treatment Response in Patient Subgroups
SNOWMASS VILLAGE, COLO.—Choosing the right treatment at the right time is the brass ring all rheumatologists hope for. Precision medicine provides the ability to leverage clinical, biomarker and omics data to predict and personalize future treatment for rheumatoid arthritis (RA). “New data and new methods to analyze the data are helping us better predict patterns…
Harnessing Genomics in the Rare Diseases Realm
ATLANTA—The increasing ease and the lowering cost of genome and exome sequencing make discovery and diagnosis of rare diseases more feasible than ever, but hurdles still need to be cleared before the world of medicine can fully harness the power of this information boom, experts said in a session at the 2019 ACR/ARP Annual Meeting….
Clinicians Discuss Current & Future Rheumatoid Arthritis Approaches
ATLANTA—When it comes to treating rheumatoid arthritis (RA) patients, most clinicians agree: One size does not fit all. Many treatment options exist, and seldom is there 100% consensus on what the first course of action or general approach should be. In the face of such variability, four clinicians took the stage at the 2019 ACR/ARP…
ARP Pre-Meeting Course Explores the Role of Precision Medicine
Precision medicine is a hot topic, but what does it mean for clinical practice in rheumatology? This year’s Annual Meeting ARP Pre-Meeting Course will explore precision medicine’s implications for biomarkers, pharmacogenomics, psychosocial aspects of care and more…
The Microbiome: A Predictor of Autoimmune Response?
CHICAGO—The world of rheumatology is beginning to harness the promise of the microbiome, with evidence showing components of the gut may help predict response to medication and may be manipulated to improve how well a treatment works, said Jose Scher, MD, at the 2019 ACR State-of-the-Art Clinical Symposium, held April 5–7. “We can truly exploit…
Recent Study Evaluates Nuclear Imaging in Interstitial Lung Disease
A recent proof-of-concept study to evaluate nuclear imaging in interstitial lung disease (ILD) concludes it is feasible to study ILD subtypes using this technology to visualize specific molecular processes of ILD. The process has important potential applications for the development of targeted molecular therapies.1 ILD is an umbrella term for a group of heterogeneous lung…
Study Shows Synovial Biopsy May Soon Lead to Precision Medicine
A confluence of advances in knowledge and technology is closing in on the day when therapies for patients with rheumatoid arthritis (RA) may be specifically targeted to the precise variant and stage of disease. “Precision medicine is in the future, and not the distant future but more in the immediate future,” says Harris R. Perlman,…
Study Finds Correlations Between Synovial Tissue & Gene Expression
Rheumatoid arthritis (RA) can be typed, grouped and categorized in different ways, and subgroup identification could help guide future research and treatment strategies based on which subtypes respond to which treatment. A new study explored an approach associating gene expression profiling with histologic analysis of synovium samples to define RA subtypes and then examined how…